NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis

ANI Pharmaceuticals, Inc. (ANIP) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ANIP

$72.24

−$0.43 (−0.59%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANIP with… →

ANIP Key Statistics

As of Oct 21, 2026
Trading
Open
$72.44
Previous Close
$72.67
Day's Range
71.96–73.51
52-Week Range
69.58–97.00
Volume
344.98K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.50
Valuation
Market Cap
$1.66B
P/E Ratio
15.64
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
7.11
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.79
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.70
EPS (ttm)Profit attributable to each share over the last twelve months.
4.62
Financials (FY)
Revenue (FY)
$883.37M+43.78%
Net Income (FY)
$78.34M
Profit marginThe share of revenue left as profit after all costs and taxes.
11.07%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
22.96M
1-Year Return
−24.26%
Dividend and dates
Earnings Date
November 6, 2026estimated
Avg Volume
377.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ANIP closed at $72.24, −24.26% over 1 year.

ANI Pharmaceuticals, Inc. (ANIP) has a market capitalization of $1.66B.

In fiscal 2025, ANIP reported revenue of $883.37M.

ANIP Stock Return by Calendar Year

ANI Pharmaceuticals, Inc. (ANIP) 10-year return: what $10,000 became

1 year
$10,000 $7,574
−24.26%
5 years
$10,000 $19,101
+91.01%
10 years
$10,000 $10,891
+8.91%

If you had invested $10,000 in ANI Pharmaceuticals, Inc. (ANIP) 10 years ago, at the close on October 21, 2016, it would have been worth $10,891 at the close on October 21, 2026: +8.91% in total, +0.86% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.49%
2025+42.80%
2024+0.25%
2023+37.06%
2022−12.70%
2021+58.68%
2020−52.91%
2019+36.98%
2018−30.15%
2017+6.32%
2016 (partial year)−9.52%

As of October 21, 2026.

ANIP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$883.37M$78.34M8.9%
2024$614.38M−$18.52M−3.0%
2023$486.82M$18.78M3.9%
2022$316.39M−$47.90M−15.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$883.37M$542.06M$81.23M$78.34M8.9%
2024$614.38M$364.17M$2.22M−$18.52M−3.0%
2023$486.82M$305.30M$49.53M$18.78M3.9%
2022$316.39M$177.60M−$25.73M−$47.90M−15.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ANIP Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricANIPDrug Manufacturers - Specialty & Generic medianvs median
P/E15.6420.3123% below
P/S ratio1.702.1019% below
Profit margin11.07%−8.14%19.2 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values ANI Pharmaceuticals, Inc. (ANIP) at $1.66B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 970.

The 52-week range on file runs from $69.58 to $97.00. ANIP last closed at $72.24 on October 21, 2026. That is −$0.43 (−0.59%) against the previous close. The latest close sits 3.82% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $883.37M. Against the prior fiscal year total of $614.38M, that is a change of +43.78%. Net income for the same year was $78.34M. The reported profit margin is 11.07%. That is 19.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 4.62.

Across the 4 fiscal years on file, revenue moves from $316.39M in 2022 to $883.37M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 15.64. That is 23.01% below the Drug Manufacturers - Specialty & Generic median of 20.31. On forward earnings the ratio is 7.11. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.79. Measured against sales, the shares trade at 1.7 times revenue. On price-to-sales that is 19.23% below the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.5. Daily returns over the trailing 10 years annualize to a volatility of 48.07%. Over the trailing twelve months the total return is −24.26%. Across 10 years the annualized return works out at +0.86%.

Growth & Income

No dividend is on file for ANIP.

So far in 2026 the total return is −8.49%. Across the complete calendar years on file, 2021 returned +58.68% and 2020 returned −52.91%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

ANI Pharmaceuticals, Inc. (ANIP) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ANI Pharmaceuticals, Inc. ANIP $1.66B 15.6
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. ANI Pharmaceuticals, Inc. trades at a P/E of 15.6.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Visit website →